A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol

Abstract Background Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer, frequently associated with incurable recurrences and distant metastases (R/M). Proliferation of SDC relies on androgen receptor (AR) signalling, prompting the use of combined androgen blockad...

Full description

Bibliographic Details
Main Authors: Jetty A. M. Weijers, Gerald W. Verhaegh, G. Lassche, Adriana C. H. van Engen-van Grunsven, Chantal M. L. Driessen, Nielka P. van Erp, Marianne A. Jonker, Jack A. Schalken, Carla M. L. van Herpen
Format: Article
Language:English
Published: BMC 2024-09-01
Series:BMC Cancer
Subjects:
Rare Cancer
Salivary Duct Carcinoma
Androgen Receptor
Combined Androgen Blockade
Androgen Deprivation Therapy
Dutasteride
Online Access:https://doi.org/10.1186/s12885-024-12889-0

Internet

https://doi.org/10.1186/s12885-024-12889-0

Similar Items